Diagnostic and Management Approaches for Pulmonary Embolism in Females of Childbearing Age

Clinical Presentation and Risk Assessment

The American Thoracic Society recommends that risk factors particularly relevant in this population include hormonal contraception/pregnancy, recent surgery/trauma, and immobilization 3
Clinical prediction tools such as the Wells score or revised Geneva score should be used to stratify pre-test probability, though D-dimer testing is not recommended to exclude PE in pregnant women (weak recommendation, very low-quality evidence) 1

The American College of Chest Physicians recommends that a structured diagnostic algorithm should begin with a chest radiograph as the first radiation-associated procedure, followed by lung scintigraphy if the chest X-ray is normal, as this approach optimizes diagnostic accuracy while minimizing radiation exposure to both mother and fetus 1, 2
If signs/symptoms of DVT are present, perform bilateral venous compression ultrasound (CUS) of lower extremities, and if CUS is positive, initiate anticoagulation treatment; if negative, proceed with further testing 1, 2
The European Society of Cardiology recommends that chest radiograph (CXR) is the first radiation-associated procedure in all cases (strong recommendation) 1, 2
Based on CXR results, if CXR is normal: Lung scintigraphy (V/Q scan) is recommended as the next imaging test rather than CT pulmonary angiography (CTPA) (strong recommendation, low-quality evidence) 1, 2

Fetal radiation exposure is minimal with both V/Q scan and CTPA, with chest X-ray: <0.01 mGy, perfusion lung scan: 0.02-0.60 mGy, and CTPA: 0.05-0.5 mGy (first trimester), increasing to 0.051-0.13 mGy (third trimester) 4, 5
Maternal breast radiation exposure is higher with CTPA (3-10 mGy) compared to V/Q scan (0.16-1.2 mGy) 6, 4

The European Society of Cardiology recommends that low molecular weight heparin (LMWH) is the treatment of choice for PE in women of childbearing age, especially during pregnancy 6, 4
Weight-adjusted dosing of LMWH should be used, with anti-Xa monitoring reserved for specific high-risk circumstances (recurrent VTE, renal impairment, extremes of body weight) 6
For pregnant women, treatment should continue for at least 6 weeks postpartum with a minimum overall treatment duration of 3 months 6, 4

The American Heart Association notes that diagnosis of PE is often delayed in younger patients due to low index of suspicion, with a mean lag time of approximately 7 days from symptom onset to definitive diagnosis 3
Overdiagnosis of PE can have significant lifelong implications for women of childbearing age, including bleeding risk during delivery, contraindications to estrogen contraception, and requirements for thromboprophylaxis during future pregnancies 6
Thrombolytic treatment should be reserved for life-threatening PE cases when surgical embolectomy is not immediately available, as it carries an 8% bleeding risk, usually from the genital tract 5